Wholesale
Wholesale pricing available
Qualify for automatic discounts at checkout when your order of wholesale eligible items hits a volume threshold.
$2,000+15% off$4,000+20% off$6,000+25% off$10,000+40% offFull wholesale details →
$260.00
Out of stock
GLP-3 Reta 30mg adjustable dose pen by Porta Biologico. Triple GLP-1, GIP, and glucagon receptor agonist. Lab tested, discreetly shipped across Canada. Intended for research purposes only.
Format30mg Pen
ConcentrationAdjustable Dosage Pen
Pack Size Selected: Single Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-3 Reta is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors; the same triple receptor mechanism as CSD’s GLP-3 RTA Triple G range from Hudson Science, iLab Pharma, and F40 Biotech. Porta Biologico’s formulation delivers this triple incretin agonist in a 30mg adjustable dose pen, adding a fourth manufacturer to CSD’s triple incretin agonist range and providing dose titration flexibility without reconstitution preparation.
The triple receptor mechanism remains consistent across all GLP-3 presentations in CSD’s range regardless of manufacturer. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, gastric emptying delay, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic effects and bone turnover research dimensions. Glucagon receptor co activation adds direct hepatic glucose output regulation, thermogenic energy expenditure stimulation through brown adipose tissue activation, and lipolytic activity in white adipose tissue. Producing the synergistic metabolic response that distinguishes triple incretin agonism from CSD’s dual GIP/GLP-1 agonist listings and the pure GLP-1 selectivity of Semaglutide.
The adjustable dose pen format allows researchers to dial precise dose increments from the 30mg total supply without reconstitution preparation, combining administration convenience with the dosing flexibility typically associated with lyophilized vial formats. This pen joins CSD’s existing adjustable dose GLP-3 RTA pens from F40 Biotech at 16mg and 40mg, with Porta Biologico’s 30mg presentation filling the mid range concentration point in CSD’s adjustable pen tier.
Porta Biologico formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s GLP-3 triple incretin agonist range now spans lyophilized vials from 10mg through 60mg across Hudson Science and iLab Pharma, the Hudson Science 10mg 5 pack, and adjustable dose pens at 16mg and 40mg from F40 Biotech and this 30mg presentation from Porta Biologico. The most comprehensive triple incretin agonist sourcing available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds and Semaglutide in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
![SEMAGLUTIDE 9.6MG PEN [WEIGHT LOSS]](https://www.canadasteroiddepot.is/wp-content/uploads/2025/10/wegovy-2.4-300x300.webp)
